Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

VIBATIV Drug Profile

« Back to Dashboard

Which patents cover Vibativ, and what substitute generic drugs are available?

Vibativ is a drug marketed by Theravance Biopharma and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-five countries.

The generic ingredient in VIBATIV is telavancin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

Summary for Tradename: VIBATIV

Patents:11
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list7
Clinical Trials: see list11
Patent Applications: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIBATIV at DailyMed

Pharmacology for Tradename: VIBATIV

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009RXYesNo6,635,618► SubscribeYY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes7,544,364► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009RXYesNo6,872,701► SubscribeY ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-001Sep 11, 2009RXYesNo7,700,550► Subscribe ► Subscribe
Theravance Biopharma
VIBATIV
telavancin hydrochloride
POWDER;IV (INFUSION)022110-002Sep 11, 2009RXYesYes6,635,618► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIBATIV

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,906,031 Polyacid glycopeptide derivatives► Subscribe
6,620,781 Glycopeptide carboxy-saccharide derivatives► Subscribe
8,859,506Glycopeptide phosphonate derivatives► Subscribe
6,872,804 Glycopeptide disulfide and thioester derivatives► Subscribe
8,541,375Glycopeptide phosphonate derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIBATIV

Country Document Number Estimated Expiration
Japan4669478► Subscribe
China100417661► Subscribe
South Korea101166250► Subscribe
European Patent Office1278549► Subscribe
Canada2411590► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIBATIV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/056United Kingdom► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
00507Netherlands► SubscribePRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
7Finland► Subscribe
11/037Ireland► SubscribePRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
2012002Lithuania► SubscribePRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc